8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 9, 2010

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 000-21846 (Commission File Number) 13-3632859 (I.R.S. Employer Identification No.)

8910 University Center Lane, Suite 660 San Diego, California (Address of principal executive offices) 92122 (Zip Code)

Registrant’s telephone number, including area code:  (858) 459-7800

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01Regulation FD Disclosure

The Registrant reported today that on December 9, 2010 at 11:30 a.m. PST it made a presentation at the 2010 LD Micro Conference in Los Angeles, California.  A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01.  The Registrant posted the investor presentation materials to its website today, December 10, 2010.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.  The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	Investor Presentation Materials

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AETHLON MEDICAL, INC.
	(Registrant)
Date: December 10, 2010	By:	/s/ James B. Frakes
		James B. Frakes
		Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Investor Presentation Materials

4

EX-99.1

Exhibit 99.1

JIM JOYCE
CHAIRMAN, CEO


LD MICRO CONFERENCE

December 9, 2010

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD
LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING
WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND
INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER
PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND
OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.

Forward looking statements

Available Conference Documents

“A Platform Technology to Address
Bioterrorism”

¤11/18/10

Shareholder Letter

¤12/1/10

California Equity Research Initiation

¤12/8/10

WE CREATE REVOLUTIONARY
DEVICES

THAT ADDRESS INFECTIOUS
DISEASE

& CANCER

THE FIRST MEDICAL DEVICE TO SELECTIVELY
FILTER VIRUSES AND IMMUNOSUPPRESSIVE
PARTICLES FROM CIRCULATION

THE HEMOPURIFIER®

Leveraging Established
Infrastructure

Selectively Targets the
Removal of:

Subtractive
Therapy

MEDICAL DEVICE VS.
BIOLOGIC REGULATORY
PATHWAY

70 TREATMENT EXPERIENCES IN
HUMANS

SUBSTANTIAL VIRAL LOAD
REDUCTION IN HIV AND HCV
INFECTED INDIVIDUALS

LEADING BROAD-
SPECTRUM
COUNTERMEASURE
AGAINST BIOTERROR &
PANDEMIC THREATS

NEAR-TERM
COMMERCIALIZATION
PATHWAY OVERSEAS

IDE ON FILE WITH THE FDA

GMPMANUFACTURING
ESTABLISHED THROUGH
PARTNERSHIP WITH
NEXTPHARMA TECHNOLOGIES

LOI SIGNED WITH MEMBRANA
FOR LARGE-SCALE
PRODUCTION

HEMOPURIFIER® PROVIDES A
PIPELINE INTO THREE $ MULTI-
BILLION MARKETS

OUR WILDCARD MARKET
OPPORTUNITY

The Most Advanced Broad-Spectrum
Countermeasure

Bioterror & Pandemic Threats

Virus	Collaborators	Human Variety
Ebola	CDC / USAMRIID	YES
Dengue	NIV / WHO	YES
Lassa	SFBR	YES
West Nile	Battelle	YES
H5N1 Avian	Battelle	YES
Spanish Flu of 1918-R	Battelle	YES
2009 H1N1 Swine	Battelle	YES
Monkey pox	Battelle	NO

“The Hemopurifier® is the onlystrategy to address the breadth of
pathogens that could be weaponized
as agents of bioterror”

Ken Alibek

OUR PRIMARY MARKET
FOCUS IS…..

TO ACCELERATE EARLY VIRAL LOAD
REDUCTION OF HCV STANDARD OF CARE
(SOC) DRUG THERAPY

Hepatitis-C Virus (HCV)

IN THE ABSENCE OF DRUG
THERAPY

5 Day HCV Treatment Studies

ONE WEEK STUDY - THREE HEMOPURIFIER®
TREATMENTS

OUR STRATEGY IS TO
COMBINE OUR
HEMOPURIFIER® WITH HCV-
SOC TO ACCELERATE EARLY
VIRAL DEPLETION

VIRAL FILTRATION HAS BEEN
PROVEN TO IMPROVE HCV
CURE RATES!

Validation for Viral Filtration
Therapy

Success
%

An Enduring Adjunct
Opportunity

¨Hemopurifier® + Current SOC

¨Hemopurifier® + Future Iterations of
SOC

¤65 drugs in competition

The Hemopurifier® + HCV SOC
Study

¨Enrollment has been initiated at the
Medicity

¨Up to 30 Patients

¨Up to 6 treatments in first 3 days of SOC

¨Clinical endpoints include:

¤Immediate Virologic Response (IVR)

¤Rapid Virologic Response (RVR)

¤Early Virologic Response (EVR)

¨Positive outcomes trigger
commercialization

OUR HEMOPURIFIER® IS THE ONLY
TREATMENT STRATEGY TO ADDRESS DRUG
RESISTANT AIDS PATIENTS

Human Immunodeficiency Virus (HIV)

DO HIV INFECTED
INDIVIDUALS HAVE TO DIE
WHEN THEY NO LONGER
RESPOND TO THEIR MEDS?

IN THE ABSENCE OF DRUG
THERAPY

HIV/AIDS Patient Data

92% reduction of viral load

Improved CD4+ T-cell %

30 DAY STUDY - THREE HEMOPURIFIER® TREATMENTS PER WEEK

AIDS

IF YOU HAVE CANCER…………

EXOSOMES ARE SECRETED BY
ALL TUMORS, LYMPHOMAS, &
LEUKEMIAS

Exosomes are
Immunosuppressive

¨Induce Apoptosis

¨Disrupt T-Cell Signaling

¨Inhibit Cytokine Production

¨Angiogenesis

¨Metastasis

Tumor-Secreted Exosomes

OUR HEMOPURIFIER® IS THE
SOLE THERAPEUTIC STRATEGY
TO ADDRESS
IMMUNSUPPRESSIVE EXOSOMES

GOAL IS TO MAXIMIZE THE
ABILITY OF THE IMMUNE
SYSTEM AND/OR OTHER
THERAPIES TO COMBAT
CANCER?

A Complementary Therapeutic

¨Targets Benefit w/o

¤Stacking additional drug
toxicity

¤Adding drug interaction risk

Recent Additions
to the AEMD
Team

September 3rd

FABIANI & COMPANY
ENGAGED

TO REESTABLISH
BIODEFENSE & PANDEMIC
THREAT PROGRAMS

October 26th

MIRIAM PROVOST NAMED
U.S. REGULATORY
ADVISOR

Miriam Provost

¨13 Years at FDA-ODE

¤Deputy Director

¤Division Director

¤Branch Chief

October 28th

ROD KENLEY NAMED
PRESIDENT

Rod Kenley

¨BAXTER

¤Conceived the HomeChoice Peritoneal Dialyzer

nInternational Marketing Manager

nDirector of Worldwide Product Planning

nDirector of Advanced Product Development

¨AKSYS LTD

¤Founder

¤Commercialized the PHD System, the first daily
home hemodialysis machine

¨DEKA RESEARCH

The HomeChoice® Device

CREATE A PORTABLE
HEMOPURIFIER® TO DELIVER
IN-HOME BENEFIT

Selected 2011 Milestone
Targets

¨HCV TREATMENT DATA

¨HCV Commercialization

¨Approval to Initiate U.S. Studies

¨Clinical Partners Established in EU

¨Multiple Bioterror Contract/Grant
Submissions

¨Cancer

¤Data from multiple studies

¤Disclosure of collaborative partnerships

¨Advance Mobile/In Home Hemopurifier®

CREATING REVOLUTIONARY
DEVICES

THAT ADDRESS INFECTIOUS
DISEASE

& CANCER

JIM JOYCE
CHAIRMAN, CEO

8910 UNIVERSITY CENTER LANE
SAN DIEGO, CA. 92122

JJ@AETHLONMEDICAL.COM
858.459.7800 X301

ASSISTANT: CHARLENE OWEN
COWEN@AETHLONMEDICAL.COM
858.459.7800 X305